PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Community Pharmacy as a Study Center for the Epidemio-logical Analysis of the Population Vaccination Against SARS-CoV-2: Regulatory Rules and Prescriptions
Dibenedetto, J.R.; Cetrone, M.; Antonacci, M.; Cannone, D.P.; Antonacci, S.; Bratta, P.; Leonetti, F.; Tricarico, D. The Community Pharmacy as a Study Center for the Epidemiological Analysis of the Population Vaccination against SARS-CoV-2: Evaluation of Vaccine Safety and Pharmaceutical Service. Pharmacy2024, 12, 16.
Dibenedetto, J.R.; Cetrone, M.; Antonacci, M.; Cannone, D.P.; Antonacci, S.; Bratta, P.; Leonetti, F.; Tricarico, D. The Community Pharmacy as a Study Center for the Epidemiological Analysis of the Population Vaccination against SARS-CoV-2: Evaluation of Vaccine Safety and Pharmaceutical Service. Pharmacy 2024, 12, 16.
Dibenedetto, J.R.; Cetrone, M.; Antonacci, M.; Cannone, D.P.; Antonacci, S.; Bratta, P.; Leonetti, F.; Tricarico, D. The Community Pharmacy as a Study Center for the Epidemiological Analysis of the Population Vaccination against SARS-CoV-2: Evaluation of Vaccine Safety and Pharmaceutical Service. Pharmacy2024, 12, 16.
Dibenedetto, J.R.; Cetrone, M.; Antonacci, M.; Cannone, D.P.; Antonacci, S.; Bratta, P.; Leonetti, F.; Tricarico, D. The Community Pharmacy as a Study Center for the Epidemiological Analysis of the Population Vaccination against SARS-CoV-2: Evaluation of Vaccine Safety and Pharmaceutical Service. Pharmacy 2024, 12, 16.
Abstract
We conducted a monocentric observational study aimed at evaluating the pharmaceutical service provided at a Community Pharmacy (C.PH.) during pandemia in our Puglia Region in the period from 29.12.2021 to 12.03.2022 on 550 patients of various ages, sexes, and with concomitant diseases. We collected anamnestic data and any post-vaccination adverse reactions. Interviews with the integrated EQ5 method on evaluating the quality of the service offered and any therapy preference were also performed. As expected, the vaccines were reactogenic after the first dose in the patients with mild-moderate reactions with younger age and female gender as risk factors. Immune-allergic reactions of moderate-severe degree were observed in adult females. In the elderly, the vaccination procedure was well tolerated. Comirnaty showed a favorable O.R.<;1 vs other vaccines. No myocarditis and thromboembolic events in our population were observed. All treatments in May 2023 were correlated with a viremia trend, Paxlovid was prescribed in 3% of the patients in our center and in 1.46% in the Puglia Region with no effects in the hospitalization. It was distributed/dispensed by a novel on behalf of third parties distribution/dispensation (D.P.C.) protocol by the C.PH. The C.PH. resulted in a safe vaccination center providing appropriate patient inclusion during vaccination.
Keywords
vaccine; SARS-CoV-2SARS-CoV-2; distribution/dispensation of behalf of third parties , D.P.C.; antivirals; prescriptions; cardiovascular reactions; observational study; Community Pharmacy, C.PH.
Subject
Medicine and Pharmacology, Pharmacy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
*
